![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 14, 2010 12:21:56 PM
Trading on the NASDAQ
January 13, 2010, 7:54 pm
The New Year is off to a great start for Oxygen Biotherapeutics, Inc. It began with the achievement of one of our major near-term goals – to get our stock listing off of the Bulletin Board and onto a major exchange. Our shares will be trading on the NASDAQ starting this Friday, January 15. I plan to be at the Exchange to ring the opening bell on Jan. 22. Watch for video of that on our website, or be at Times Square in New York City for viewing on the big screen.
Having our shares listed on the NASDAQ will give our company visibility to a broad range of potential investors who could not or would not have considered investing in our stock when it was on the Bulletin Board. Most of the big institutional investors (mutual funds, pension funds, etc.) will not buy penny stocks (which we were pre-split) nor buy shares that are not traded on a major exchange. Likewise, many retail brokerage firms cannot recommend such stocks to their clients. Being listed on the NASDAQ could lead to greater interest in our common stock by the broader financial community and the investing public. This re-listing is an important opportunity to position our company where we believe it belongs. It will give us the potential financial strength needed to become a company with multiple products in various development stages.
Speaking of multiple products, at today’s OneMedForum conference, I mentioned our plans for new product developments. I think some of those plans are pretty exciting.
First of all, we’re adding an additional pillar to our business strategy – veterinary products. Our research has come up with an animal wound-care product line for topical application. It takes the healing ability of Oxycyte™ in a gel form and makes it available to apply to pets, farm animals, etc. Because it is a topical product line for animals, we believe we can bring it to market very quickly. If you think about how much Americans spend on their pets, you can see that the potential could be very significant. Our goal is to have these products, which we have tentatively named OxyBioPet, on the market this year.
We plan to follow that with a second veterinary product line, which we are initially calling OxyBioVet. This would be an intravenous Oxycyte emulsion veterinarians could use to carry oxygen to an animal’s heart, brain or other organs. While I am not willing, right now, to predict the timing for a market launch, the requirements for animal products are far less restrictive than for humans.
At the same investor conference, I also briefly mentioned our plans to expand our cosmetic product line this year. We are targeting this spring to roll out our Dermacyte Eye Cream. It is formulated for those fine line wrinkles around the eyes. We will also launch another formulation as a face lotion, and a repackaged version of our cosmetic concentrate gel, which we recently tested in blister packs via on-line sales. As a fourth product, we’re considering the Dermacyte Oxygenating Solution (DOS). Think of it as a perfluorocarbon liquid in its basic, clear form – not a gel or a cream but the PFC liquid with its ability to capture oxygen from the air and carry it through the outer skin layer.
Meanwhile, our TBI clinical trials are under way. It’s not likely that we will be providing any additional information until some time after the first cohort has been treated and the results analyzed. While enrollment of the first patient was delayed for reasons previously explained, I’m confident that we’re on a time line to complete the trial in the targeted 12 to 18 months.
2010 began with a major milestone and I expect the whole year to bring others. Thank you for your support. Stay tuned; stay healthy, wealthy, and safe. God bless.
Recent TENX News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/30/2024 08:20:02 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/23/2024 08:31:39 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/19/2024 10:48:03 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/19/2024 08:15:15 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/15/2024 08:19:12 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/14/2024 10:47:35 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/14/2024 07:19:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:45:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:30:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:35:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 11:43:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 11:42:23 PM
- Biotech Soars Following Oversubscribed $100M Private Placement Announcement • AllPennyStocks.com • 08/06/2024 08:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:23:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:32:09 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/24/2024 08:31:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:01:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:00:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:01:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 01:01:43 PM
- Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM